Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 35-43, February 2007

Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity

  • Danielle Duffy
    • ,
  • Daniel Rader

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Daniel Rader, The Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA. Tel.: (+1) 215-573-4176; fax: (+1) 215-573-8606.

Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA 19107

The Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1050-1738(06)00175-7

doi:10.1016/j.tcm.2006.11.003

Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 35-43, February 2007

Article Tools

* Image Usage & Resolution